Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.
- SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.
- Revenues for the second quarter ending June 30, 2023 were $0.0 million compared to $0.0 million for the same period in 2022.
- Revenues were negligible in both periods because no manufacturing of commercial products occurred in the second quarter in 2023 or 2022.
- Research and development (R&D) expense for the second quarter of 2023 was $0.4 million compared to $3.2 million in the second quarter of the prior year.